| Type | Title | Date Released | |
|---|---|---|---|
SCHEDULE 13G/A | Soleus Capital Master Fund, L.P. (Filed by) New | ||
144 | Form 144 New | ||
8-K | Novocure Receives FDA Not Approvable Letter for Optune Mya® Premarket Approval Application New | ||
4 | Puri Michal Nath (Reporting) | ||
S-8 | Form S-8 | ||
8-K | Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance | ||
10-Q | Form 10-Q | ||
8-K | Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer | ||
8-K | NovoCure Limited Announces Retirement of Director Timothy Scannell | ||
8-K | NovoCure Limited Reports Cybersecurity Incident | ||
144 | Form 144 | ||
8-K | Novocure Reports Record Second Quarter 2026 Financial Results |